Imiquimod: A potential role in dermatology?

British Journal of Dermatology

Volumn 147, Issue 1, 2002, Pages 1-6

  Eedy, D J ^a  

^a Royal Victoria Hospitals Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PODOPHYLLIN; PODOPHYLLOTOXIN; SULINDAC; TOLL LIKE RECEPTOR; TRICHLOROACETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; KERATOSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SKIN CARCINOMA; SKIN IRRITATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VERRUCA VULGARIS;

AMINOQUINOLINES; CONDYLOMATA ACUMINATA; DERMATOLOGIC AGENTS; HUMANS; INTERFERON INDUCERS; KERATOSIS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 0036068725     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04945.x     Document Type: Review

References (71)

1. Imiquimod applied topically: A novel immune response modifier and new class of drug
2. Immunomodulatory and pharmacological properties of imiquimod
3. Toll-like receptors: Critical proteins linking innate and acquired immunity
4. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
5. Cytokine induction in mice by the immunomodulator imiquimod
6. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463
7. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro
8. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609
9. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
10. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells
11. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression
12. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production
13. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts
14. Self administered topical 5% imiquimod cream for external anogenital warts
15. Treatment of human papilloma virus in a 6-month old infant with imiquimod 5% cream
16. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream
17. Imiquimod in clinical practice
18. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women
19. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily or three times a day
20. A randomized controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod
21. Management of anogenital warts (condylomata acuminata)
22. Treatment of anogenital warts
23. Epidemiology of genital human papillomavirus infection
24. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma
25. Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males
26. Safety and efficacy of imiquimod 5% cream in the treatment of penile warts in uncircumcised men when applied three times weekly or once per day
27. Treatment of genital warts with an immune-response modifier (imiquimod)
28. Direct medical costs for surgical and medical treatment of condylomata acuminata
29. The cost-effectiveness of patient-applied versus provider administered intervention strategies for the treatment of external genital warts
30. Modeling the impact of treatment options in genital warts: Patient-applied versus physician-administered therapies
31. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
32. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
33. Treatment of warts with immune response modifiers
34. Imiquimod for plantar and periungual warts
35. Treatment of recalcitrant plantar warts with imiquimod
36. Imiquimod: A new possibility for treatment-resistant verrucae planae
37. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children
38. Treatment of molluscum contagiosum with topical 5% imiquimod cream
39. Imiquimod therapy for molluscum contagiosum
40. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream; a placebo-controlled, double-blind study
41. Immunomodulatory therapy in the management of viral infections in patients with HIV infection
42. Topical imiquimod treatment of human papillomavirus in a patient with human immunodeficiency virus
43. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus
44. Lip papillomatosis in immunodeficiency: Therapy with imiquimod
45. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod
46. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient
47. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease
48. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection
49. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases
50. Topical imiquimod to treat intraepidermal carcinoma
51. Detection of human papillomavirus and responses to topical 5% imiquimod in a case of stucco keratosis
52. Porokeratosis of Mibelli: Successful treatment with 5% imiquimod cream
53. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with imiquimod 5%
54. Penile intraepithelial neoplasia: Clinical spectrum and treatment of 35 cases
55. Imiquimod 5% cream in the treatment of Bowen's disease
56. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy
57. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, Sulindac: Potential applications for this combination of immunotherapy
58. Specific inhibition of cyclooxygenase 2 restores antitumour reactivity by altering the balance of IL-10 and IL-12 synthesis
59. Topical imiquimod 5% cream in the treatment of Bowen's disease of the penis
60. Treatment of Bowen's disease of the penis with imiquimod
61. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream
62. Successful treatment of anogenital Bowen's disease with the immunomodulator imiguimod, and monitoring of therapy by DNA image cytometry
63. Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream
64. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell naevus syndrome patient
65. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-weeks dose-response trial
66. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion
67. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
68. Imiquimod: A novel treatment for lentigo maligna
69. Treatment of lentigo maligna with imiquimod
70. Topical imiquimod treatment of a cutaneous melanoma metastasis
71. Topical imiquimod in the treatment of metastatic melanoma to the skin